News Overview

Phialogics AG


We are a preclinical company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases. We engineer next generation biologics that rebalance the immune response in acute and chronic inflammation.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.